VEGFA and macular retinal edema: Triamcinolone has been shown to inhibit the expression of the vascular endothelial growth factor (VEGF), in addition to anti-inflammatory properties, anti-permeability function, and neuroprotective effects; Anti-VEGF agents, such as bevacizumab, exert direct, strong inhibition of VEGF.[10] Several studies involving a reduction in macular edema due to CRVO with triamcinolone or bevacizumab have revealed promising results.[11–14] However, the series in which macular edema due to CRVO with 20/200 or worse visual acuity was studied, it has analyzed fewer samples.